Should I buy or sell Soleno Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks .

What is Soleno Therapeutics' stock price target for 2024?

5 brokerages have issued twelve-month target prices for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $93.00. On average, they predict the company's stock price to reach $55.60 in the next year. This suggests a possible upside of 48.4% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts .

How have SLNO shares performed in 2024?

Soleno Therapeutics' stock was trading at $40.25 at the start of the year. Since then, SLNO shares have decreased by 6.9% and is now trading at $37.46. View the best growth stocks for 2024 here .

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SLNO earnings forecast .

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.02.

What ETF holds Soleno Therapeutics' stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 2,327 shares of SLNO stock, representing 0.85% of its portfolio.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , OPKO Health (OPK) , ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Miragen Therapeutics (MGEN) , Vaxart (VXRT) , Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD) .

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Bhatnagar Anish , Jack W Schuler , James H Mackaness , Kristen Yen and Perceptive Advisors Llc. View institutional ownership trends .

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free SLNO Stock Alerts

$37.46

-0.44 (-1.16%)

(As of 09:46 AM ET)

Compare

Today's Range: $37.16
▼
$37.96
50-Day Range: $37.14
▼
$52.35
52-Week Range: $3.16
▼
$53.82

Volume: 2,221 shs
Average Volume: 296,541 shs
Market Capitalization: $1.22 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.60

Get Soleno Therapeutics alerts:

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 48.4% Upside
$55.60 Price Target
Short Interest: Bearish
14.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 1.17
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.23 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.23) to ($0.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

148th out of 914 stocks

Electromedical Equipment Industry

3rd out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Soleno Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.60% of the float of Soleno Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Soleno Therapeutics has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Soleno Therapeutics has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soleno Therapeutics does not currently pay a dividend.
Dividend Growth
Soleno Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Soleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Soleno Therapeutics is -0.55.

2.3

News and Social Media Coverage

News Sentiment
Soleno Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Soleno Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,231,489.00 in company stock.
Percentage Held by Insiders
23.70% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($1.23) to ($0.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soleno Therapeutics is -12.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soleno Therapeutics is -12.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soleno Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLNO Stock News Headlines

April 4, 2024 | insidertrades.com

Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of Stock

April 5, 2024 | investing.com

Soleno Therapeutics CEO sells over $780k in company stock

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 4, 2024 | finance.yahoo.com

Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)

April 4, 2024 | finance.yahoo.com

CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)

March 16, 2024 | finance.yahoo.com

SLNO Apr 2024 40.000 put

March 16, 2024 | finance.yahoo.com

SLNO Apr 2024 35.000 put

March 11, 2024 | bizjournals.com

Construction of Soleno's $22M pipe factory in Saratoga underway

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

March 11, 2024 | finance.yahoo.com

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

March 8, 2024 | globenewswire.com

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 8, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

March 7, 2024 | investorplace.com

SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023

March 6, 2024 | globenewswire.com

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

February 24, 2024 | thestreet.com

Soleno Therapeutics Inc.

February 22, 2024 | finance.yahoo.com

SLNO Apr 2024 65.000 call

February 22, 2024 | finance.yahoo.com

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 22, 2024 | globenewswire.com

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 18, 2024 | ca.finance.yahoo.com

SLNO Mar 2024 40.000 call

February 18, 2024 | finance.yahoo.com

SLNO Mar 2024 22.500 put

February 17, 2024 | ca.finance.yahoo.com

SLNO Mar 2024 60.000 call

February 17, 2024 | finance.yahoo.com

SLNO Mar 2024 45.000 put

February 14, 2024 | finance.yahoo.com

Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why

February 14, 2024 | msn.com

Sage Therapeutics GAAP EPS of -$0.55 beats by $0.76, revenue of $77.97M beats by $16.99M

February 1, 2024 | investing.com

Soleno Therapeutics Inc (SLNO)

February 1, 2024 | msn.com

Soleno Therapeutics Expands Equity Incentive Plan

February 1, 2024 | finance.yahoo.com

Soleno Therapeutics to Present at Upcoming February Investor Conferences

See More Headlines

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:SLNO
CUSIP: N/A
CIK: 1484565
Web: www.soleno.life
Phone: (650) 213-8444
Fax: 650-213-8383
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $55.60
High Stock Price Target: $93.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +46.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,990,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -79.65%
Return on Assets: -52.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.89
Quick Ratio: 14.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.16 per share
Price / Book: 7.34

Miscellaneous

Outstanding Shares: 32,460,000
Free Float: 24,768,000
Market Cap: $1.23 billion
Optionable: Optionable
Beta: -1.56

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Anish Bhatnagar M.D. (Age 54)
President, CEO, COO & Director
Comp: $835.2k
Mr. James H. MacKaness (Age 60)
Chief Financial Officer
Comp: $539k
Ms. Patricia C. Hirano (Age 58)
Vice President of Regulatory Affairs
Comp: $423.8k
Dr. Neil M. Cowen M.B.A.
Ph.D., Senior Vice President of Drug Development
Ms. Meredith Manning M.B.A. (Age 51)
Chief Commercial Officer
Ms. Kristen Yen M.S. (Age 55)
Vice President of Clinical Operations
Comp: $317.19k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLNO Stock Analysis - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings or view top-rated stocks.
What is Soleno Therapeutics' stock price target for 2024?: 5 brokerages have issued twelve-month target prices for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $93.00. On average, they predict the company's stock price to reach $55.60 in the next year. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts.
How have SLNO shares performed in 2024?: Soleno Therapeutics' stock was trading at $40.25 at the start of the year. Since then, SLNO shares have decreased by 6.9% and is now trading at $37.46.
View the best growth stocks for 2024 here.
When is Soleno Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SLNO earnings forecast.
How were Soleno Therapeutics' earnings last quarter?: Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.02.
What ETF holds Soleno Therapeutics' stock?: Virtus LifeSci Biotech Clinical Trials ETF holds 2,327 shares of SLNO stock, representing 0.85% of its portfolio.

When did Soleno Therapeutics' stock split?: Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Soleno Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).
Who are Soleno Therapeutics' major shareholders?: Soleno Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen and Perceptive Advisors Llc.
View institutional ownership trends.
How do I buy shares of Soleno Therapeutics?: Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLNO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Soleno Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Soleno Therapeutics Stock (NASDAQ:SLNO)

SLNO Stock Price History

SLNO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SLNO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™